华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例

杨杨; 顾晓琳; 何静松; 胡永仙; 蔡真

doi:10.1631/jzus.B2300835

Your Location：

Home >

Browse articles >

华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例

Scan for full text

文章被引用时，请邮件提醒。

Submit

Correspondence | Updated：2024-08-19

华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例
Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2024年25卷第8期页码：719-722
Affiliations：

1.Bone Marrow Transplantation Center, Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
2.Department of Hematology, Putuo People’s Hospital, Zhoushan 316100, China
Funds：

the Zhejiang Key Research and Development Project(2020C03014);We thank Dr. Xiaoping SUN from the University of Texas MD Anderson Cancer Center;for editing
DOI：10.1631/jzus.B2300835
中图分类号：
CSTR：
纸质出版日期： 2024-08-15 ，

收稿日期： 2023-11-16 ，

修回日期： 2024-01-05 ，
Accepted：

杨杨,顾晓琳,何静松等.华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(08):719-722.

Yang YANG, Xiaolin GU, Jingsong HE, et al. Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(8):719-722.
杨杨,顾晓琳,何静松等.华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(08):719-722. DOI： 10.1631/jzus.B2300835.

Yang YANG, Xiaolin GU, Jingsong HE, et al. Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(8):719-722. DOI： 10.1631/jzus.B2300835.

摘要

华氏巨球蛋白血症（WM）是一种罕见的小淋巴细胞、浆细胞样淋巴细胞和浆细胞肿瘤，会累及骨髓，甚至累及淋巴结和脾，通常与克隆性IgM球蛋白血症相关。尽管WM通常伴有惰性临床病程，但却无法治愈。本研究报告了一个具有挑战性的WM案例。该患者在化疗、免疫治疗和布鲁顿酪氨酸激酶（BTK）抑制剂治疗后出现复发/难治性病变，并累及髓外，但在CD19定向嵌合抗原受体T（CAR-T）细胞治疗后病情得到改善。此外，我们还回顾了文献中报道的CAR-T细胞治疗WM病例。本案例中的患者已接受一年多的随访，其病情仍保持良好的部分缓解状态，这表明CAR-T细胞疗法具有作为复发/难治性WM替代方案的潜力。人们迫切希望进行更大规模的临床研究来评估这种疗法的有效性和安全性。

Abstract

关键词

华氏巨球蛋白血症嵌合抗原受体T（CAR-T)细胞治疗复发和难治性

Keywords

references

Abeykoon JP, Zanwar S, Ansell SM, et al., 2021. Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. Am J Hematol, 96(8):945-953. https://doi.org/10.1002/ajh.26210https://doi.org/10.1002/ajh.26210

Bansal R, Jurcic JG, Sawas A, et al., 2020. Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia. Leuk Lymphoma, 61(2):465-468. https://doi.org/10.1080/10428194.2019.1665668https://doi.org/10.1080/10428194.2019.1665668

Castillo JJ, Meid K, Flynn CA, et al., 2020. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv, 4(16):3952-3959. https://doi.org/10.1182/bloodadvances.2020001963https://doi.org/10.1182/bloodadvances.2020001963

Castillo JJ, Allan JN, Siddiqi T, et al., 2022. Venetoclax in previously treated Waldenström macroglobulinemia. J Clin Oncol, 40(1):63-71. https://doi.org/10.1200/JCO.21.01194https://doi.org/10.1200/JCO.21.01194

Gertz MA, 2023. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol, 98(2):348-358. https://doi.org/10.1002/ajh.26796https://doi.org/10.1002/ajh.26796

Kastritis E, Morel P, Duhamel A, et al., 2019. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia, 33(11):2654-2661. https://doi.org/10.1038/s41375-019-0431-yhttps://doi.org/10.1038/s41375-019-0431-y

Kyriakou C, 2018. High-dose therapy and hematopoietic stem cell transplantation in Waldenström macroglobulinemia. Hematol Oncol Clin North Am, 32(5):865-874. https://doi.org/10.1016/j.hoc.2018.05.013https://doi.org/10.1016/j.hoc.2018.05.013

Locke FL, Ghobadi A, Jacobson CA, et al., 2019. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol, 20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7https://doi.org/10.1016/S1470-2045(18)30864-7

Owen RG, Treon SP, Al-Katib A, et al., 2003. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol, 30(2):110-115. https://doi.org/10.1053/sonc.2003.50082https://doi.org/10.1053/sonc.2003.50082

Palomba ML, Qualls D, Monette S, et al., 2022. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. J Immunother Cancer, 10(2):e004128. https://doi.org/10.1136/jitc-2021-004128https://doi.org/10.1136/jitc-2021-004128

Ruan G, Zanwar S, Abeykoon JP, et al., 2020. Predictors of short-term survival in Waldenström macroglobulinemia. Leuk Lymphoma, 61(12):2975-2979. https://doi.org/10.1080/10428194.2020.1789625https://doi.org/10.1080/10428194.2020.1789625

Shadman M, Yeung C, Redman MW, et al., 2023. CD20 CAR-T therapy with MB-106 for BTK inhibitor-refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) ‒ single institution study. HemaSphere, 7(S3):e68877ca. https://doi.org/10.1097/01.HS9.0000971284.68877.cahttps://doi.org/10.1097/01.HS9.0000971284.68877.ca

Thompson PA, Tam CS, 2023. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood, 141(26):3137-3142. https://doi.org/10.1182/blood.2023020240https://doi.org/10.1182/blood.2023020240

Treon SP, 2015. How I treat Waldenström macroglobulinemia. Blood, 126(6):721-732. https://doi.org/10.1182/blood-2015-01-553974https://doi.org/10.1182/blood-2015-01-553974

Treon SP, Tedeschi A, San-Miguel J, et al., 2023. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria. Semin Hematol, 60(2):97-106. https://doi.org/10.1053/j.seminhematol.2023.03.009https://doi.org/10.1053/j.seminhematol.2023.03.009

浏览量

Downloads

CSCD

工具集

关联资源

暂无数据